Treats alcohol dependence. ANDA 91205, held by Accord Hlthcare. Naltrexone Hydrochloride.
As of Nov 16, 2026, ANDA 91205 (Naltrexone Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Aug 17, 2011, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Naltrexone hydrochloride tablets USP 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone hydrochloride tablets USP 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Naltrexone Hydrochloride50MG · tablet;oral | Naltrexone Hydrochloride | Rx |
| May 14, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 17, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters